Skip to main content

Table 3 Risk factors associated with occurrence of MEE in EGPA patients

From: Intractable middle ear effusion in EGPA patients might cause permanent hearing loss: a case–control study

Variables

Crude HR (95% CI)

P-value

Adjusted HR (95% CI)

P-value

Age, years

0.97 [0.94–1.01]

0.157

1.05 [0.97– 1.13]

0.206

Females (vs males)

0.72 [0.30–1.70]

0.442

22.7 [0.87–593.88]

0.061

History of MEE before diagnosis

2.82 [1.01–7.88]

0.048

1.31 [0.13–13.38]

0.819

PNS abnormalities at diagnosis

2.48 [0.73–8.50]

0.147

2.8 [0.01–691.93]

0.712

Major organ involvement at diagnosis

1.89 [0.73–4.91]

0.190

65.44 [1.50–2838.39]

0.030

Eosinophil count at diagnosis

1.00 [0.99–1.00]

0.985

1.00 [0.99–1.00]

0.077

ESR level at diagnosis

1.02 [1.00–1.03]

0.099

1.02 [1.00– 1.05]

0.062

CRP lever at diagnosis

1.03 [0.96–1.12]

0.417

1.00 [0.74–1.36]

1.000

Continuing the maintenance steroid without cessation

0.48 [0.18–1.25]

0.132

8.59 [1.13– 65.42]

0.038

Early onset of ear symptom after systemic therapy (< 6 Months)

4.53 [1.42–14.47]

0.011

40.0 [1.35–1183.43]

0.033

  1. CI, Confidence interval; EGPA, Eosinophilic granulomatosis with polyangiitis; HR, Hazard ratio; MEE, Middle ear effusion; PNS, Paranasal sinus